| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 22.2MM | -23% |
| Gross Profit | 11MM | - |
| Cost Of Revenue | 11.2MM | -9% |
| Operating Income | -63.9MM | -2% |
| Operating Expenses | 74.9MM | - |
| Net Income | -62.9MM | +2% |
| R&D | 55.7MM | -4% |
| G&A | 19.1MM | -17% |
| Interest Expense | 1.4MM | -16% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.
Key Insights Significantly high institutional ownership implies REGENXBIO's stock price is sensitive to their trading...
By Karen Roman REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients. Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its potential one-time gene therapy for the treatment of so-called wet AMD. “We believe that there […]
REGENXBIO Inc. (Nasdaq: RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and tolerability of a single dose of subretinal ABBV-RGX-314 for the treatment of wet age-related macular degeneration (wet AMD). Two-year data were published in The Lancet in a paper titled "Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study." These positive study results informed the ongoing pi
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days on Wednesday, April 3, 2024.
Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, has reported an insider sale according to a recent SEC filing.
The threat is still emerging, but it could be significant.
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences:
Regenxbio Inc (NASDAQ:RGNX), a biotechnology company focused on the development, commercialization, and licensing of recombinant viral vectors for use in gene therapy, has reported an insider sale according to a recent SEC filing.
The latest analyst coverage could presage a bad day for REGENXBIO Inc. ( NASDAQ:RGNX ), with the analysts making...